JW Life Science

JW Life Science Current Assets

The Current Assets of JW Life Science (234080.KS) as of Oct 21, 2026 is 31.82 B KRW. In the previous year, Current Assets was 95.70 B KRW — a change of -66.74% (lower).

Current Assets

31.82 BKRW

YoY

-66.74%

Last updated:

Current Assets of JW Life Science is 2025 31.82 B KRW. Current Assets of JW Life Science was 2024 95.70 B KRW. It decreases by -66.74% lower compared to the previous year.

The JW Life Science Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
45.12 B KRW
Jan 1, 2019
50.04 B KRW
Jan 1, 2020
53.40 B KRW
Jan 1, 2021
58.31 B KRW
Jan 1, 2022
76.02 B KRW
Jan 1, 2023
79.31 B KRW
Jan 1, 2024
95.70 B KRW
Jan 1, 2025
31.82 B KRW
The JW Life Science Current Assets history
YEARCurrent AssetsYoY
31.82 BKRW-66.74%
95.70 BKRW+20.66%
79.31 BKRW+4.33%
76.02 BKRW+30.38%
58.31 BKRW+9.20%
53.40 BKRW+6.70%
50.04 BKRW+10.93%
45.12 BKRW-17.43%
54.64 BKRW+16.63%
46.85 BKRW+23.53%
37.92 BKRW+3.32%
36.70 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JW Life Science Stock analysis

What does JW Life Science do? JW Life Science Corp. manufactures intravenous fluids including basic IV fluids with water, electrolytes, and glucose, nutrient infusion solutions containing amino acids, lipids, proteins, vitamins, and minerals, and special infusion solutions for specific medical cases. The company produces total parenteral nutrition (TPN) products as part of its manufacturing focus. The primary buyers of these products are healthcare providers and hospitals requiring intravenous treatments for patient care. The company serves the medical sector by providing essential fluid and nutrition solutions for clinical use. The firm's product segments are defined by the types of IV fluids and TPN solutions they produce, targeting healthcare institutions that administer intravenous therapies. Basic IV fluids are used for general hydration and electrolyte balance, while nutrient infusion solutions support patient nutrition in critical care settings. Special infusion solutions address unique medical conditions requiring tailored treatments. The company's offerings are integral to hospital and clinic operations in delivering patient care. JW Life Science Corp. generates revenue through the sale of its manufactured intravenous fluid products to healthcare facilities. The company's business model relies on consistent demand for IV fluids and TPN solutions within the medical industry. Its products are distributed to hospitals and clinics that require these essential medical supplies for patient treatment protocols. JW Life Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JW Life Science stock

Current Assets of JW Life Science is 31.82 B KRW in 2025.

Current Assets of JW Life Science changed from 95.70 B KRW to 31.82 B KRW, representing a -66.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets JW Life Science since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's JW Life Science historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — JW Life Science

All Key Metrics — JW Life Science